Vanguard Natural Resources LLC (VNR) Financials Nov 14,
Vanguard Natural Resources LLC (VNR) Financials Nov 14, 2014, 8:01 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Vanguard Natural Resources LLC
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 46.04M 85.36M 312.84M 310.36M 443.25M
Cost of Goods Sold (COGS) incl. D&A 31.11M 47.54M 177.42M 208.28M 273.04M
COGS excluding D&A 16.5M 25.31M 92.57M 103.74M 105.5M
Depreciation & Amortization Expense 14.61M 22.23M 84.86M 104.54M 167.54M
Depreciation - - - 1.3M 2.79M
Amortization of Intangibles - - - 103.24M 164.75M
Gross Income 14.93M 37.82M 135.42M 102.08M 170.21M
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 10.64M 10.13M 19.78M 22.47M 25.94M
Research & Development 0 0 0 0 0
Other SG&A 10.64M 10.13M 19.78M 22.47M 25.94M
Other Operating Expense 0 0 0 0 40.43M
Unusual Expense 130.81M (7.45M) 6M 205.2M 10.27M
EBIT after Unusual Expense (130.81M) 7.45M (6M) (205.2M) (10.27M)
Non Operating Income/Expense 35.07M (7.48M) 7.48M (1.34M) 27.09M
Non-Operating Interest Income 0 1,000 0 0 0
Equity in Affiliates (Pretax) 0 0 0 0 -
Interest Expense 4.28M 5.77M 28.99M 41.89M 61.15M
Gross Interest Expense 4.28M 5.77M 28.99M 41.89M 61.15M
Interest Capitalized 0 0 0 0 0
Pretax Income (95.74M) 21.89M 88.13M (168.82M) 59.51M
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 0 - -
Income Tax - Current Foreign 0 0 0 - -
Income Tax - Deferred Domestic 0 0 0 - -
Income Tax - Deferred Foreign 0 0 0 - -
Income Tax Credits 0 0 0 - -
Equity in Affiliates 0 0 0 0 -
Other After Tax Income (Expense) 0 0 - 0 0
Consolidated Net Income (95.74M) 21.89M 88.13M (168.82M) 59.51M
Minority Interest Expense 0 0 26.07M 0 0
Net Income (95.74M) 21.89M 62.06M (168.82M) 59.51M
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 - 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (95.74M) 21.89M 62.06M (168.82M) 59.51M
Preferred Dividends 0 0 0 0 2.63M
Net Income Available to Common (95.74M) 21.89M 62.06M (168.82M) 56.88M
EPS (Basic) (6.74) 1.00 1.95 (3.11) 0.78
Basic Shares Outstanding 14.21M 21.92M 31.79M 54.2M 72.64M
EPS (Diluted) (6.74) 1.00 1.95 (3.11) 0.77
Diluted Shares Outstanding 14.21M 21.96M 31.85M 54.2M 72.99M
EBITDA 18.89M 49.91M 200.5M 184.16M 271.37M
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A New Era for Young Learners in Bellevue When a community-driven school like BASIS Independent Bellevue makes a move to expand, it doesn't happen in a vacuum. They're not just building another campus—they're aiming to sculpt the future right here in Bellevue, and boy, do they have a plan. The new Lower School campus opening come Fall 2027 is dedicated to kiddos in...
Continue Reading
Smirnoff's Bold Move to Ride Marvel's Coattails Here we are, watching a vodka brand hitch its wagon to a Hollywood juggernaut. Smirnoff has announced a fan experience to toast Marvel Studios' "Avengers: Doomsday." Of course, this isn't just about clinking glasses; it's a marketing stunt dressed in superhero tights. The impressive part? They’re selling the razzmatazz for...
Continue Reading
Shifting Gears at Ameritas: New VP Takes the Helm Well, chalk one up for Ameritas on this move. They've just brought on Ying Zhao as the new vice president of actuarial and financial strategy. It's a mouthful of a title, sure, but it's the role itself that's worth watching. Ameritas, for those not tracking, is a major player in the insurance and financial universe, doing...
Continue Reading
Amgen Prepares to Reveal Third Quarter 2026 Financials If there's one thing I've learned about investing, it's that the devil's in the details, and Amgen's (NASDAQ:AMGN) upcoming webcast for its third quarter 2026 financial results is exactly the kind of detail that sets market-watchers' hearts racing. Scheduled for November 3, just after the U.S. markets close, this is...
Continue Reading
Analyzing Royce Global Trust's Approach When you dig into the Royce Global Trust portfolio, what emerges is a tapestry woven through decades of grit and determination in the investing world. This closed-end fund, trading under the symbol NYSE: RGT, is no stranger to the ebbs and flows of global markets. With every tick of the clock, speculation dances around this fund's...
Continue Reading
Turning Talk into Triumphs Award chatter isn't exactly rare in this industry, but the latest accolades rolling in for transcosmos from the Best Contact Center Indonesia 2026 ain't your run-of-the-mill pat on the back. Sure, a trophy's a trophy, but when they snatch Gold in the Business Contribution category and another shiny Silver in People Development, it’s hinting at...
Continue Reading
New Awards Shine Light on Corporate Legal Teams Here's one for the books: Bloomberg Law is rolling out a shiny new awards program called Inside In-House: Legal Departments of the Year. Now, this isn't some vanity affair because it's aimed at celebrating the folks in legal teams who make companies tick behind the scenes. Openings for nominations run through November 20,...
Continue Reading
Oracle Lays Down a Bold Gauntlet Oracle Corporation (NYSE: ORCL) sure knows how to draw the spotlight. With their recent Investor Day in Vegas, they've laid out ambitions that could make even the most seasoned Wall Streeter spit out their coffee. Who would've thought they'd be betting on a whopping $225 billion in revenue by FY30? That's supposed to be a more than 35%...
Continue Reading
Could This Be the Breakthrough for Portal Hypertension? Now, here's something that might just turn a few heads in the medical world. BD has launched their Liverty™ TIPS Stent Graft in the U.S., a move set to shake up the landscape for treating portal hypertension. This isn't just another shiny new gadget—it's a promise of more personalized patient care in a field...
Continue Reading
When you dive into the world of biopharma, you never quite know what's going to grab your attention next. Today, it's Ascletis Pharma's (HKEX: 1672) GLP-1 receptor agonist, ASC30, that's piqued my interest. It just wrapped up a U.S. Phase II study with a bang, showing off with some impressive results for type 2 diabetes treatment. This ain't no half-hearted...
Continue Reading
Top 5 Most Recently Viewed Articles
The Expanding Landscape of the Automotive Key Blank Market The automotive key blank market is experiencing a transformative phase, poised to grow from USD 6.29 billion in 2025 to an impressive USD 9.67 billion by 2034. This remarkable growth reflects the industry’s ongoing adaptation to technological advancements, particularly the rising adoption of smart and automated...
Continue Reading
Insights into the Expanding Meat Processing Equipment Market The global meat processing equipment market is anticipated to experience significant growth, projected to reach USD 16.36 billion by 2032. This remarkable increase from its value of USD 11.25 billion in 2024 represents a robust compounded annual growth rate (CAGR) of 4.86% from 2025 to 2032. The factors driving...
Continue Reading
Fed's Waller Emphasizes Importance of Rate Cuts Christopher Waller, a Governor at the Federal Reserve, has spoken out about the economic challenges facing the labor market. He is advocating for a reduction in the Fed’s policy rate during the next meeting, scheduled for December. His approach centers on the need to address the risks associated with a weakening labor...
Continue Reading
Global Initiative on Ageing and Longevity Launches U.S. Chapter The Global Initiative on Ageing and Longevity (GIA-L) has propelled its mission forward by launching a North American Chapter. This initiative is designed to accelerate innovation and foster significant business growth while addressing the changing demographics and needs of an aging population. The GIA-L...
Continue Reading
Investigating Extreme Networks: What You Need to Know Faruqi & Faruqi, LLP, a well-known national securities law firm, is currently looking into possible claims on behalf of investors in Extreme Networks, Inc. (NASDAQ: EXTR). The firm is reaching out to investors who have incurred losses exceeding $100,000 to discuss their options and legal rights. With the situation...
Continue Reading